EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase in Plasmodium vivax

Wenqi Zheng, Shitong Cheng, Fei Liu, Xinxin Yu, Yan Zhao, Fan Yang, Sataporn Thongpoon, Wanlapa Roobsoong, Jetsumon Sattabongkot, Enjie Luo, Liwang Cui, Yaming Cao

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1451063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Wenqi Zheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Plasmodium vivax, Malaria Vaccines, Antibodies, Protozoan, Malaria, Vivax. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Health Research Institutes, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transmission-blocking vaccines (TBVs) can effectively prevent the community’s spread of malaria by targeting the antigens of mosquito sexual stage parasites. At present, only a few candidate antigens have demonstrated transmission-blocking activity (TBA) potential in P. vivax . Quiescin-sulfhydryl oxidase (QSOX) is a sexual stage protein in the rodent malaria parasite Plasmodium berghei and is associated with a critical role in protein folding by introducing disulfides into unfolded reduced proteins. Here, we reported the immunogenicity and transmission-blocking potency of the PvQSOX in P. vivax . Methods and findings The full-length recombinant PvQSOX protein (rPvQSOX) was expressed in the Escherichia coli expression system. The anti-rPvQSOX antibodies were generated following immunization with the rPvQSOX in rabbits. A parasite integration of the pvqsox gene into the P. berghei pbqsox gene knockout genome was developed to express full-length PvQSOX protein in P. berghei (Pv-Tr-PbQSOX). In western blot, the anti-rPvQSOX antibodies recognized the native PvQSOX protein expressed in transgenic P. berghei gametocyte and ookinete. In indirect immunofluorescence assays, the fluorescence signal was detected in the sexual stages, including gametocyte, gamete, zygote, and ookinete. Anti-rPvQSOX IgGs obviously inhibited the ookinetes and oocysts development both in vivo and in vitro using transgenic parasites. Direct membrane feeding assays of anti-rPvQSOX antibodies were conducted using four field P. vivax isolates (named isolates #1–4) in Thailand. Oocyst density in mosquitoes was significantly reduced by 32.00, 85.96, 43.52, and 66.03% with rabbit anti-rPvQSOX antibodies, respectively. The anti-rPvQSOX antibodies also showed a modest reduction of infection prevalence by 15, 15, 20, and 22.22%, respectively, as compared to the control, while the effect was insignificant. The variation in the DMFA results may be unrelated to the genetic polymorphisms. Compared to the P.vivax Salvador (Sal) I strain sequences, the pvqsox in isolate #1 showed no amino acid substitution, whereas isolates #2, #3, and #4 all had the M361I substitution.

Conclusions

Our results suggest that PvQSOX could serve as a potential P. vivax TBVs candidate, which warrants further evaluation and optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium vivaxMalaria VaccinesAntibodies, ProtozoanMalaria, VivaxPlasmodium bergheiRecombinant ProteinsAnimalsRabbitsMiceEscherichia coliAntigens, ProtozoanProtozoan ProteinsFemaleHumansImmunogenicity, VaccineMice, Inbred BALB C

Stichwörter der Autor:innen

DMFASPlasmodium vivaxquiescin sulfhydryl oxidasetransgenic parasitetransmission-blocking vaccine

Substanzen

Malaria VaccinesAntibodies, ProtozoanRecombinant ProteinsAntigens, ProtozoanProtozoan Proteins

Autor:innen und Institutionen

  • Department of Immunology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
  • Department of Clinical Laboratory Medicine, Affiliated Hospital of Inner Mongolian Medical University, Hohhot, China.
  • National Clinical Research Center for Laboratory Medicine, Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, China.
  • Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Salaya, Thailand.
  • Department of Pathogen Biology, College of Basic Medical Sciences, China Medical University, Shenyang, China.
  • Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States.

Förderung

  • NIAID NIH HHS
  • National Health Research Institutes
  • National Natural Science Foundation of China
  • Natural Science Foundation of Inner Mongolia Autonomous Region

Zitieren

APA

Zheng, W., Cheng, S., Liu, F., Yu, X., Zhao, Y., Yang, F., Thongpoon, S., Roobsoong, W., Sattabongkot, J., Luo, E., Cui, L., & Cao, Y. (2024). Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase in Plasmodium vivax. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1451063

Vancouver

Zheng W, Cheng S, Liu F, Yu X, Zhao Y, Yang F, et al. Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase in Plasmodium vivax. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1451063

BibTeX
@article{Zheng2024,
  author = {Zheng, Wenqi and Cheng, Shitong and Liu, Fei and Yu, Xinxin and Zhao, Yan and Yang, Fan and Thongpoon, Sataporn and Roobsoong, Wanlapa and Sattabongkot, Jetsumon and Luo, Enjie and Cui, Liwang and Cao, Yaming},
  title = {Immunogenicity and transmission-blocking potential of quiescin sulfhydryl oxidase in Plasmodium vivax},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1451063}
}
Kostenlos starten →